These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34478262)

  • 1. Penetration Cascade of Size Switchable Nanosystem in Desmoplastic Stroma for Improved Pancreatic Cancer Therapy.
    Zhao X; Yang X; Wang X; Zhao X; Zhang Y; Liu S; Anderson GJ; Kim SJ; Li Y; Nie G
    ACS Nano; 2021 Sep; 15(9):14149-14161. PubMed ID: 34478262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sono-promoted drug penetration and extracellular matrix modulation potentiate sonodynamic therapy of pancreatic ductal adenocarcinoma.
    Xiao H; Li X; Li B; Zhong Y; Qin J; Wang Y; Han S; Ren J; Shuai X
    Acta Biomater; 2023 Apr; 161():265-274. PubMed ID: 36893956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment.
    Chen X; Jia F; Li Y; Deng Y; Huang Y; Liu W; Jin Q; Ji J
    Biomaterials; 2020 Jul; 246():119999. PubMed ID: 32247201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors.
    Hong E; Barczak W; Park S; Heo JS; Ooshima A; Munro S; Hong CP; Park J; An H; Park JO; Park SH; La Thangue NB; Kim SJ
    Cell Death Dis; 2023 Feb; 14(2):93. PubMed ID: 36765032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer.
    Lee JE; Lee P; Yoon YC; Han BS; Ko S; Park MS; Lee YJ; Kim SE; Cho YJ; Lim JH; Ryu JK; Shim S; Kim DK; Jung KH; Hong SS
    Biomed Pharmacother; 2023 Jun; 162():114716. PubMed ID: 37086509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
    Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
    Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-stroma TGF-β1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin α
    Nan P; Dong X; Bai X; Lu H; Liu F; Sun Y; Zhao X
    Cancer Lett; 2022 Mar; 528():59-75. PubMed ID: 34958892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer.
    Geismann C; Morscheck M; Koch D; Bergmann F; Ungefroren H; Arlt A; Tsao MS; Bachem MG; Altevogt P; Sipos B; Fölsch UR; Schäfer H; Müerköster SS
    Cancer Res; 2009 May; 69(10):4517-26. PubMed ID: 19435915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1.
    Ottaviano AJ; Sun L; Ananthanarayanan V; Munshi HG
    Cancer Res; 2006 Jul; 66(14):7032-40. PubMed ID: 16849548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer-Associated Fibroblast-Targeted Delivery of Captopril to Overcome Penetration Obstacles for Enhanced Pancreatic Cancer Therapy.
    Chen X; Jia F; Huang Y; Jin Q; Ji J
    ACS Appl Bio Mater; 2022 Jul; 5(7):3544-3553. PubMed ID: 35786827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential delivery of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer.
    Feng J; Xu M; Wang J; Zhou S; Liu Y; Liu S; Huang Y; Chen Y; Chen L; Song Q; Gong J; Lu H; Gao X; Chen J
    Biomaterials; 2020 May; 241():119907. PubMed ID: 32120315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.
    Zhao J; Xiao Z; Li T; Chen H; Yuan Y; Wang YA; Hsiao CH; Chow DS; Overwijk WW; Li C
    ACS Nano; 2018 Oct; 12(10):9881-9893. PubMed ID: 30231203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas.
    Neuzillet C; de Gramont A; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
    Oncotarget; 2014 Jan; 5(1):78-94. PubMed ID: 24393789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
    Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors.
    Zinger A; Koren L; Adir O; Poley M; Alyan M; Yaari Z; Noor N; Krinsky N; Simon A; Gibori H; Krayem M; Mumblat Y; Kasten S; Ofir S; Fridman E; Milman N; Lübtow MM; Liba L; Shklover J; Shainsky-Roitman J; Binenbaum Y; Hershkovitz D; Gil Z; Dvir T; Luxenhofer R; Satchi-Fainaro R; Schroeder A
    ACS Nano; 2019 Oct; 13(10):11008-11021. PubMed ID: 31503443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
    Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
    Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically Relevant Biology of Hyaluronic Acid in the Desmoplastic Stroma of Pancreatic Ductal Adenocarcinoma.
    Jahedi H; Ramachandran A; Windsor J; Knowlton N; Blenkiron C; Print CG
    Pancreas; 2022 Oct; 51(9):1092-1104. PubMed ID: 37078930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.